Table 2:
Study population characteristics.
| Survived with no/mild MRI Injury (n=56) | Death or Severe MRI Injury (n=24) | P value | |
|---|---|---|---|
| Gestational Age | 38.54 ± 1.67 | 39.04 ± 1.88 | 0.238 |
| Birth Weight | 3.20 ± 0.60 | 3.24 ± 0.66 | 0.793 |
| Gender (% male) | 62.5 | 50.0 | 0.330 |
| Race (%) | 0.654 | ||
| Caucasian | 42.9 | 41.7 | |
| Black | 50.0 | 50.0 | |
| Asian | 3.6 | 0.0 | |
| Other | 3.6 | 8.3 | |
| Ethnicity (% Hispanic) | 10.7 | 4.2 | 0.668 |
| Delivery (% cesarean) | 69.6 | 70.8 | 1.000 |
| Apgar 5 mina [median (range)] | 4 (0–9) | 3 (0–6) | 0.023 |
| Apgar 10 minb [median (range)] | 5 (0–8) | 4 (0–10) | 0.118 |
| Initial pHc | 6.97 ± 0.23 | 6.90 ± 0.20 | 0.193 |
| Initial Base Deficitd | 18.11 ± 5.00 | 20.48 ± 6.09 | 0.099 |
| Sarnat Stage III-Severe Encephalopathy (% Severe) | 5.4 | 45.8 | 0.000 |
| HOL at aEEG Start [median (range)] | 11.8 (4.9–22.1) | 9.1 (3.8–16.9) | 0.086 |
| Total EEG Recording Time | 78.58 ± 0.1.36 | 75.32 ± 3.45 | 0.817 |
| DOL at Time of MRI [median (range)] | 9 (4–16) | 10 (7–15) | 0.107 |
| Seizures (% electrographic) | 19.6 | 58.3 | 0.001 |
| Treatment for seizures (% treated) | 32.1 | 79.2 | 0.000 |
| Sedation (%) | 0.854 | ||
| None | 12.5 | 8.3 | |
| Intermittent | 50 | 54.2 | |
| Continuous | 37.5 | 37.5 | |
*
Data listed as mean ± SD unless otherwise specified.
a
Data available for 55/56 and 23/24 patients in the favorable and adverse outcome groups respectively.
b
Data available for 47/56 and 23/24 patients in the favorable and adverse outcome groups respectively.
c
Data available for 55/56 and 24/24 patients in the favorable and adverse outcome groups respectively.
d
Data available for 50/56 and 20/24 patients in the favorable and adverse outcome groups respectively.
HOL= hour of life; DOL= day of life